医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

United Health Products Inc. Signs HemoStyp Product Distributors

2013年10月18日 PM09:55
このエントリーをはてなブックマークに追加


 

WESTBURY, N.Y.

United Health Products, Inc. (OTCQB: UEEC) announced that it has engaged two distributors, Nu Spectrum Solutions LLC and Critical Health Products Ltd, to market and sell its proprietary and patented HemoStypTM products. The exclusive agreements for specific markets include suggested initial stocking inventories and require yearly minimums.

Nu Spectrum Solutions LLC

Nu Spectrum Solutions has been granted the exclusive rights to sell to the US military and worldwide equestrian markets. Nu Spectrum Solutions LLC President, George Prussin, said “My extensive experience in the field tells me that the equestrian market for HemoStyp is an important and valuable one.” Prussin’s horse, Safely Kept, is in the Breeders’ Cup Hall of Fame. Prior to his involvement with the Breeders’ Cup, Prussin founded Shali Leasing and built it to a $1+ billion revenue company. For more information, please visit: http://nuspecmed.com/.

Critical Health Products Ltd

Critical Health Products was granted the exclusive right to all HemoStyp products (excluding equestrian) for sale and distribution in Australia, Oceania, and Southeast Asia. Ian French, President of Critical Health Products, said, “While the market for HemoStyp products is extremely broad, our initial focus will be centered on the first responder and medical communities.” Subsequently French will tap into his extensive experience and relationships with the Australian Armed Forces. For more information, please visit: http://www.criticalhealthcare.com.

Benefits of HemoStypTM

  • HemoStyp is an all-natural product comprised of regenerated oxidized cellulose gauze which is specifically formulated to aid in the process of hemostasis (clotting) when positioned on a cut or wound.
  • Unlike the other products in the wound care market, HemoStyp contains no potentially harmful chemicals or animal byproducts and is hypoallergenic.
  • Once it has completed its task, it is easily removed by dissolving it in water or saline solution. This method of removal neither disturbs the clotted surface nor encourages re-bleeding.

United Health Products continues to pursue multiple markets for HemoStyp including medical, dental and sports.

About United Health Products, Inc.

United Health Products, Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStypTM, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com.

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

CONTACT

Company Contact:
United Health Products, Inc.
Dr.
Philip Forman, CEO
877-358-3444
or
IR Contact:
Bibicoff
+ MacInnis, Inc.
Terri MacInnis, Dir. of IR
818-379-8500
terri@bibimac.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent